As on Wednesday, Allogene Therapeutics Inc (NASDAQ: ALLO) got off with the flyer as it spiked 8.89% to $1.47, before settling in for the price of $1.35 at the close. Taking a more long-term approach, ALLO posted a 52-week range of $0.86-$3.78.
It was noted that the giant of the Healthcare sector posted annual sales growth of 6.26% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 6.26%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 27.78%. This publicly-traded company’s shares outstanding now amounts to $220.13 million, simultaneously with a float of $152.97 million. The organization now has a market capitalization sitting at $326.17 million. At the time of writing, stock’s 50-day Moving Average stood at $1.1630, while the 200-day Moving Average is $1.4809.
Allogene Therapeutics Inc (ALLO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Allogene Therapeutics Inc’s current insider ownership accounts for 31.06%, in contrast to 60.66% institutional ownership. According to the most recent insider trade that took place on Jun 10 ’25, this organization’s Director sold 36,885 shares at the rate of 1.42, making the entire transaction reach 52,377 in total value, affecting insider ownership by 107,431.
Allogene Therapeutics Inc (ALLO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
Allogene Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 27.78% and is forecasted to reach -0.89 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.75% through the next 5 years, which can be compared against the 6.26% growth it accomplished over the previous five years trading on the market.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Let’s observe the current performance indicators for Allogene Therapeutics Inc (ALLO). It’s Quick Ratio in the last reported quarter now stands at 8.92.
In the same vein, ALLO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.11, a figure that is expected to reach -0.22 in the next quarter, and analysts are predicting that it will be -0.89 at the market close of one year from today.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Through scrutinizing the latest numbers posted by the [Allogene Therapeutics Inc, ALLO], it can be observed that its last 5-days Average volume of 2.63 million was lower the volume of 4.17 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 82.01% While, its Average True Range was 77.88.
Raw Stochastic average of Allogene Therapeutics Inc (ALLO) in the period of the previous 100 days is set at 68.83%, which indicates a major fall in contrast to 97.14% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.0749 that was lower than 0.0895 volatility it exhibited in the past 100-days period.
